MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- SHASUN PHARMA - TEVA PHARMA (Israel)
SHASUN PHARMA vs TEVA PHARMA (Israel) - Comparison Results
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 SHASUN PHARMA  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SHASUN PHARMA Mar-14 |
TEVA PHARMA Dec-13 |
SHASUN PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 94 | 2,951 | - | |
| Low | Rs | 46 | 2,564 | - | |
| Sales per share (Unadj.) | Rs | 214.2 | 1,693.9 | - | |
| Earnings per share (Unadj.) | Rs | 5.3 | 105.8 | - | |
| Cash flow per share (Unadj.) | Rs | 15.8 | 242.7 | - | |
| Dividends per share (Unadj.) | Rs | 1.00 | 92.63 | - | |
| Dividend yield (eoy) | % | 1.4 | 3.4 | 42.6% | |
| Book value per share (Unadj.) | Rs | 53.3 | 1,881.6 | - | |
| Shares outstanding (eoy) | m | 56.62 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 0.3 | 1.6 | 20.0% | |
| Avg P/E ratio | x | 13.1 | 26.1 | 50.3% | |
| P/CF ratio (eoy) | x | 4.4 | 11.4 | 38.9% | |
| Price / Book Value ratio | x | 1.3 | 1.5 | 89.4% | |
| Dividend payout | % | 18.7 | 87.5 | 21.4% | |
| Avg Mkt Cap | Rs m | 3,958 | 2,338,521 | 0.2% | |
| No. of employees | `000 | NA | 44.9 | 0.0% | |
| Total wages/salary | Rs m | 2,164 | 0 | - | |
| Avg. sales/employee | Rs Th | NM | 31,959.1 | - | |
| Avg. wages/employee | Rs Th | NM | 0 | - | |
| Avg. net profit/employee | Rs Th | NM | 1,996.5 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 12,127 | 1,436,403 | 0.8% | |
| Other income | Rs m | 229 | 0 | - | |
| Total revenues | Rs m | 12,356 | 1,436,403 | 0.9% | |
| Gross profit | Rs m | 1,009 | 393,360 | 0.3% | |
| Depreciation | Rs m | 594 | 116,106 | 0.5% | |
| Interest | Rs m | 415 | 28,213 | 1.5% | |
| Profit before tax | Rs m | 230 | 249,041 | 0.1% | |
| Minority Interest | Rs m | 0 | 1,131 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -163,482 | 0.0% | |
| Tax | Rs m | -73 | -3,041 | 2.4% | |
| Profit after tax | Rs m | 302 | 89,731 | 0.3% | |
| Gross profit margin | % | 8.3 | 27.4 | 30.4% | |
| Effective tax rate | % | -31.7 | -1.2 | 2,593.1% | |
| Net profit margin | % | 2.5 | 6.2 | 39.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 6,884 | 970,141 | 0.7% | |
| Current liabilities | Rs m | 8,456 | 846,045 | 1.0% | |
| Net working cap to sales | % | -13.0 | 8.6 | -150.0% | |
| Current ratio | x | 0.8 | 1.1 | 71.0% | |
| Inventory Days | Days | 62 | 91 | 67.9% | |
| Debtors Days | Days | 108 | 96 | 112.1% | |
| Net fixed assets | Rs m | 4,970 | 469,161 | 1.1% | |
| Share capital | Rs m | 113 | 3,536 | 3.2% | |
| Net worth | Rs m | 3,020 | 1,595,571 | 0.2% | |
| Long term debt | Rs m | 1,817 | 734,465 | 0.2% | |
| Total assets | Rs m | 13,347 | 3,282,641 | 0.4% | |
| Interest coverage | x | 1.6 | 9.8 | 15.8% | |
| Debt to equity ratio | x | 0.6 | 0.5 | 130.7% | |
| Sales to assets ratio | x | 0.9 | 0.4 | 207.6% | |
| Return on assets | % | 5.4 | 3.6 | 149.6% | |
| Return on equity | % | 10.0 | 5.6 | 177.9% | |
| Return on capital | % | 13.3 | 4.9 | 270.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 398 | 228,888 | 0.2% | |
| From Investments | Rs m | -1,635 | -81,104 | 2.0% | |
| From Financial Activity | Rs m | 1,309 | -274,567 | -0.5% | |
| Net Cashflow | Rs m | 71 | -126,783 | -0.1% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 70.71 Rs / USD
Compare SHASUN PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare SHASUN PHARMA With: WYETH LTD STERLING BIOTECH PIRAMAL ENTERPRISES TORRENT PHARMA ALEMBIC LTD
|
| |
Today's Market
Sensex Trades in Green; Tata Motors & Yes Bank Top Gainers(12:30 pm)
Share markets in India are presently trading on a positive note tracking global cues. The BSE Sensex is trading up by 133 points while the NSE Nifty is trading up by 46 points.
Related Views On News
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Use My Secret to Increase Your Trading Profits Today
Dec 10, 2019What to do after every trade.
A Simple, 7-Step Checklist for Your Trading Success
Dec 4, 2019What we can learn from one of the greatest traders to have ever lived.
Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020 (Profit Hunter)
Dec 5, 2019This corner of the market could provide more returns than blue chips in 2020.
What Is the IPO Euphoria Signaling Us About the Markets? (The 5 Minute Wrapup)
Dec 2, 20192019 will be remembered as the year of great money-making IPOs...
Make the Most of the Smallcap Rebound with These Stocks (Profit Hunter)
Dec 3, 2019Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
More|
| |
SHASUN PHARMA SHARE PRICE
Nov 17, 2015 (Close)
TRACK SHASUN PHARMA
- Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SHASUN PHARMA
SHASUN PHARMA - VENUS REMEDIES COMPARISON
COMPARE SHASUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.